ABSTRACT Somatic cell nuclear transplantation (SCNT) and induced pluripotent stem cell (iPSC) technologies can be employed to change cell fate by reprogramming. The discoveries of SCNT and iPSCs were awarded the Nobel Prize for Physiology and Medicine in 2012, which reaffirmed the importance of cell fate plasticity. However, the low cloning efficiency of SCNT and differences between iPSCs and embryonic stem cells (ESCs) are great barriers and may be caused by incomplete or aberrant reprogramming. Additionally, the well characterized reprogramming factors Oct4, Sox2, Klf4 and c-Myc (OSKM) are not simultaneously expressed at high levels in enucleated or early embryonic oocytes, suggesting reprogramming may be different in the above two methods. Recent studies have demonstrated that small molecules and specific proteins expressed in oocytes and in early embryonic development play important roles in reprogramming by replacing transcription factors, erasing reprogramming memory and accelerating the speed and extent of reprogramming. In this review, we summarize the current state of SCNT and iPSCs technologies and discuss the latest advances in the research of proteins and small molecules affecting SCNT and iPSCs. This is an area of research in which chemical biology and proteomics are combining to facilitate improving cellular reprogramming and production of clinical grade iPSCs.
Introduction
Each and every one of us developed from a totipotent egg following fertilization, and the journey of embryonic development from immature to specialized cells was previously considered to be unidirectional. However, in 1962, Gurdon (Gurdon, 1962) provided the first evidence that broke from this dogmatic view and demonstrated that specialization of cells is reversible by somatic cell nuclear transplantation (SCNT) in frogs. Since then, SCNT has been used to clone sheep (Wilmut et al., 1997) and pigs (Betthauser et al., 2000) , and following great efforts, SCNT-derived human embryonic stem cells (ESCs) were finally generated from fetal dermal fibroblasts in 2013 (Tachibana et al., 2013) and from 35-and 75-year-old males in 2014 (Chung et al., 2014) . Subsequently, adult somatic nuclei from newborn and adult female patients with type 1 diabetes were reprogrammed in to diploid pluripotent stem cells. This work showed the potential for therapeutic applications (Yamada et al., 2014) and confirmed the suitability of SCNT for large mammals, and the research area tors playing important roles in the maintenance of ESCs' identity also play pivotal roles in the induction of pluripotency in somatic cells. Takahashi et al., acquired iPSCs from mouse and human somatic cells using retroviruses, and these cells have the ability to replicate indefinitely while maintaining pluripotency and the ability to differentiate into cells of all three germ layers Yamanaka, 2006, Yu et al., 2007) . These cells circumvent the need for human embryos and can reduce or avoid immune rejection by generating stem cells from the patient's own cells. Therefore, iPSCs provide an attractive alternative to ESCs and hold great promise for disease modeling, drug selection and cell therapies in both regenerative medicine and agriculture . A year after human iPSCs were generated for the first time, various disease-specific iPSCs were produced that offer an unprecedented opportunity to recapitulate both normal and diseased human tissues in vitro (Park et al., 2008) . Owing to the capacity of proliferating indefinitely, iPSCs show a high efficiency for gene targeting (Hockemeyer et al., 2009) , which may have implications for treating diseases resulting from genetic defects. In 2013, using human iPSCs-derived cardiomyocytes from patients with hereditary cardiac disorders, Liang et al., (Liang et al., 2013) demonstrated the power of patient-specific iPSCs in drug selection and drug toxicity screening for establishing the optimum drug dosage for specific patients. However, low efficiency, genome instability and epigenetic memories of donor cells during reprogramming remain barriers to the future clinical use of iPSCs.
At present, achieving a perfect reprogramming method appears to be some way off. A recent comparison of SCNT and iPSCs technologies found that both can cause subtle molecular defects (Krupalnik and Hanna, 2014) . In this review, we further explore the similarities, differences and the advantages, disadvantages of these methods. Compared to SCNT, iPSCs and early embryos may provide insight into possible perfect reprogramming approaches, and may be useful for identifying proteins and small molecules in oocytes or early embryos that may be critical for this process. To this end, we have reviewed the source and function of such proteins and small molecules reported to date, and summarized the recent advances in SCNT and iPSCs technologies. The most promising approaches for producing high quality, safe and effective pluripotent stem cells using proteins and small molecules are given particular attention.
The current state of SCNT and associated problems
SCNT is a method of creating reconstructed embryos from somatic cells and oocytes that consists of implanting a donor nucleus from a somatic cell into an enucleated oocyte. This approach has produced viable offspring of a number of species for reproductive purposes, and has also generated patient-specific stem cell lines for therapeutic purposes (Fig. 1) . Since the birth of Dolly the sheep, SCNT has been used to clone cattle (Cibelli et al., 1998) , mice (Wakayama et al., 1998) , goats (Baguisi et al., 1999) , pigs (Polejaeva et al., 2000) , cats (Shin et al., 2002) , rabbits (Chesne et al., 2002) , horses (Galli et al., 2003) , rats (Zhou et al., 2003) , dogs (Lee et al., 2005) , and ferrets (Li et al., 2006) from a range of cell types (Table 1) . Human ESCs (hESCs) have also been generated using SCNT and shown to be equivalent to ESCs from embryos in vivo studies (Chung et al., 2014 , Tachibana et al., 2013 , Yamada et al., 2014 .
Despite multiple attempts, the efficiency of producing viable offspring by SCNT remains stubbornly low 
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Note: none represents no related information in the research.
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Through the ectopic expression of defined factors in mouse embryonic or adult fibroblasts, these differentiated cells can be reprogrammed to iPSCs (Takahashi and Yamanaka, 2006) . Since iPSCs were first described, the use of these cells in the development of reprogramming technologies has been rapid, and numerous types of source cells have been employed. Researchers also use different methods to obtain iPSCs, including viral-and transgene-free methods, non-viral methods, and viral methods (Table 3) . Though the last two methods are considered to take risk of genome integration, the first method is still immature, and further studies are needed for optimizing reprogramming process.
In general, these approaches up-regulate genes involved in pluripotency and self-renewal, and down-regulate lineage commitment genes (Krueger et al., 2010) . Current prevailing reprogramming methods affect the quality of iPSCs and great strides have been made to improve the safety, efficiency and speed of these methods. In summary, eliminating oncogenes and adding new factors such as Sall4, Tbx3 and Nr5a2 into reprogramming cocktails, adjusting existing factor combinations, and altering the proteins and small compounds present to reduce tumorigenicity have all been shown to affect the quality of the iPSCs produced (Han et al., 2010 , Tsubooka et al., 2009 . The stoichiometry of factors and the order in which they are introduced can also affect the speed and efficiency of reprogramming . For instance, iPSCs based on tetraploid complementation that were generated in mouse embryonic fibroblasts (MEFs) by ectopic Sall4, Nanog, Esrrb, and Lin28 (SNEL) were of higher quality than classic Oct4, Sox2, Klf4 and c-Myc (OSKM)-derived cells (Buganim et al., 2014) .
At present, iPSCs technologies face the problems of reprogramming extent, memory, and immunogenicity. The pluripotent genes Fbx15, Oct4 and Nanog combined with drug-resistance genes and cloning morphologies have been used to screen positive cell lines (Takahashi and Yamanaka, 2006) . At the early stages of reprogramming, iPSCs are always partially reprogrammed and possess limited differentiation potential. For example, the first iPSCs line could not produce adult chimeras and exhibited no germ transmission capacity (Okita et al., 2007, Takahashi and Yamanaka, 2006) . However, these partially reprogrammed cells proved powerful for investigation of reprogramming mechanisms. Meanwhile, partially reprogrammed iPSCs can elicit immune rejection (Martins-Taylor and Xu, 2012 , Polo et al., 2010 . Although controversy concerning the immunogenicity of iPSCs remains all the time, the immunogenicity of iPSCs generated by a viral integration approach was higher than that of cells derived by an episomal method without genomic integration (Zhao et al., 2011 
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immunogenicity. On the other hand, the origin of the cell type can also influence the immune properties of iPSCs, possibly due to differences in reprogramming memory (Polo et al., 2010) . The difference in transcription and epigenetic landscape between ESCs and iPSCs is that the latter type bearing some memory of their original differentiated state (Eguchi et al., 2014) . The memory of iPSCs can result in the partial retention of the transcriptional and epigenetic features of the source cells. Additionally, iPSCs tend to differentiate into source cells when differentiation is induced. Interestingly, this phenomenon gradually disappears with multiple passages . In 2013, Kumar et al., (Kumar et al., 2013) found that inducing the enzyme cytidine deaminase could diminish the epigenetic memory of iPSCs, resulting in a stable pluripotent state.
Proteins and small molecules in SCNT and iPSCs
In 1981, mouse ESCs (mESCs) were obtained from blastocyst pluripotent epiblast cells and cultured with inactivated fibroblast feeders, serum and other ingredients (Evans and Kaufman, 1981) . It was found that cytokines from the feeder cells or serum such as leukegmia inhibitory factor (Lif) (Gardner and Brook, 1997) and bone morphogenetic protein (BMP) (Ying et al., 2003) were essential for maintenance of pluripotency. Approximately 20 years later, hESCs were first reported (Thomson et al., 1998) . In apparent contrast to mESCs, Lif (Humphrey et al., 2004 , Thomson et al., 1998 and BMP (Xu et al., 2002) have been shown to induce differentiation in hESCs. In contrast, basic fibroblast growth factor (bFGF) greatly promoted the self-renewal of hESCs (Amit et al., 2000) . Therefore, researchers realized small molecules may cause distinct states of pluripotent in stem cells in mouse and human. In 2009, Nichols and Smith (Nichols and Smith, 2009) proposed that two phases of pluripotency can be defined: naïve and primed. The mESCs are naïve pluripotent state and lead to broad and more robust developmental potential relative to primed mouse epiblast cells and hESCs. Then, Hanna et al., (Hanna et al., 2010) acquired naïve human ESCs/iPSCs which could grow on feeder cells in PD0325901/CHIR99021/Lif/Forskolin. After that, Ware et al., (Ware et al., 2014 ) also described two routes to generate naïve hESCs by some small molecules and proteins like MEK/ERK and GSK3 inhibitors with FGF2. These studies suggest that specific proteins and small molecules play an important role in establishing and maintaining the pluripotency of ESCs among different species, and even the pluripotent state can inter-convert through different combinations of small compouds and proteins.
Small molecules can be highly influential in reprogramming procedures. During the early stages of reprogramming, activation of the toll-like receptor 3 (TLR3) innate immunity pathway was shown to be required for efficient nuclear reprogramming by comparing the viral and protein delivery of reprogramming factors (Lee et al., 2012) . Furthermore, TLR3 activation was implemented by Poly I:C, a type of TLR3 agonist. More recently, Notch inhibition was shown to facilitate oncogene-independent generation of mouse and human iPSCs (Ichida et al., 2014) .
One hypothesis that accounts for the enhanced reprogramming capacity posits that current strategies for inducing pluripotent stem cells lack oocyte-specific factors (Gonzalez-Munoz et al., 2014) such as BMPs, GDF9 (Paradis et al., 2009 ) and ASF1A (Kocabas et al., 2006) that are specifically enriched in oocytes,early embryos. Furthermore, these factors could also contribute to achieving more efficient reprogramming and illuminating the molecular pathways involved (Table 4 ). There are many more factors in oocytes and early embryos that may perform vital functions in reprogramming, many of which are untested for iPSCs generation (Table 5) 
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Note: SCF, stem cell factor; Deng's factors are VPA, CHIR99021, 616452, Tranylcypromine, Forskolin, DZNep and TTNPB.
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Advantages and strategies of using proteins and small molecules in reprogramming
Proteins and small molecules can be used to regulate biological processes including reprogramming and have distinct advantages over other approaches. Firstly, they can be synthesized in large quantities and stored for long periods until needed. Secondly, the effects are usually reversible and can often be tightly controlled by duration and concentration. Lastly, owing to their stability and easy manipulation, they are suitable for academic and industrial applications. Numerous proteins and small molecules, whether from feeder cells, serum or synthesized, have proved useful for establishing and maintaining ESCs, and many play vital roles in reprogramming, which allows genetic-free manipulation of stem cells . Besides, reseachers identified small molecules can enhance genome editing in pluripotent stem cells through the CRISPR/Cas9 technology, thus the use of small molecules provides a simple and effective strategy to enhance precise genome engineering applications and facilitates the study of DNA repair mechanisms (Yu et al., 2015) .
Hamatani et al., (Hamatani et al., 2008) also proposed that genome-wide gene expression data could be obtained from microscopic specimens such as oocytes and pre-implantation embryos due to technological advances. Understanding the highly fluctuating dynamics of proteins and small molecules in oocytes and early embryos will be invaluable for identifying novel factors and mechanisms governing reprogramming. However, discovering and characterizing these crucial molecular determinants of reprogramming remains a challenging task.
On the one hand, the low efficiency of somatic cells cloning using SCNT is a major barrier to the successful application of this technology, and our understanding of the mechanisms underlying nuclear reprogramming in SCNT must be expanded. The use of SCNT for generating stem cells from humans and other primates has been questioned for a variety of ethical and technical reasons. Furthermore, since the discovery of iPSCs, there has emerged a large body of opposition to the use of SCNT in humans, including therapeutic cloning. In contrast, the use of iPSCs holds tremendous potential for developing cell-based therapies for degenerative diseases, drug screening, and developing disease models via production of patient-specific stem cells (Peters et al., 2010) . In September 2014, iPSCs were trialed for the first time, on a 70-year-old Japanese woman with a debilitating eye disease (http://www.nature.com/news/japanese-woman-is-first-recipientof-next-generation-stem-cells-1.15915). Researchers around the world have since been watching closely to see whether the cells can prevent further destruction of the retina while avoiding side effects such as inducing an immune reaction or inducing cancerous growth. Therefore, more and more such clinical trials are needed to confirm the safety of iPSCs for medical applications.
It is widely appreciated that the oocyte cytoplasmic milieu is the major factors controlling the conversion of differentiated somatic cells to pluripotent stem cells. For example, the oocyte factors BMPs, vimentin and GDF9 are known to play important roles in nuclear reprogramming and iPSCs generation. Notably, the same oocyte factors have opposite effects in different cell types or species. For instance, BMPs suppress differentiation in mouse ESCs (Ying et al., 2003) and promote somatic cell reprogramming in early mice embryos (Samavarchi-Tehrani et al., 2010) , but arrest human somatic cell reprogramming (Chen et al., 2013b) . Researchers must therefore pay particular attention when translating results between species.
Conclusion
Procedures for cellular reprogramming and for using iPSCs in clinical applications must be safe, rapid and effective, and should generate high quality pluripotent stem cells that are stable and reproducible. Reprogramming methods using SCNT and iPSCs have shown great potential. Since Dolly the sheep, SCNT has proven more popular for animal cloning experiments, although the use of methods employing iPSCs is growing. Rodriguez et al., (Rodriguez et al., 2012) investigated signalling pathways participating in the formation of the porcine inner cell mass, and this knowledge could be applied to the development of porcine iPSCs. Perfect 
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reprogramming and production of high quality iPSCs remain the major targets, and expanding our knowledge of early embryonic development and ESCs differentiation will be important for achieving these aims. For instance, in 2015, Irie et al., (Irie et al., 2015) generated human primodial germ cells (PGCs) from ESCs and high quality naïve state iPSCs, and Sox17 is a critical specifier of human PGCs fate, it may contribute to a major ultimate goal for human health (Barrios et al., 2013) . High-throughput or next-generation sequencing is continuing to improve at pace, and is making increasingly important contributions to clinical and industrial applications. For example, de novo sequencing, whole genomes and transcriptomes resequencing, and single cell sequencing are now possible for detecting dymanic changes in reprogramming process. These powerful technologies have the potential to greatly expand our understanding of the mechanisms underlying reprogramming, and will assist our pursuit of perfect reprogramming methods.
In summary, both SCNT and iPSCs are highly influenced by specific proteins and small molecules that are present in oocytes and early embryos. This review has attempted to emphasize the pivotal roles that these proteins and small molecules play in governing somatic cell reprogramming.
